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It is recommended that specialist surgeons treat all breast cancer, although the limited evidence to support this is based on treatment
patterns prior to the introduction of screening. Whether a specialist survival advantage exists in the post-screening era is uncertain, as
referral and treatment patterns may have changed, in addition to the effect of screening on the natural history of breast cancer. Our
aim was to determine the impact of screening on the caseload and case-mix of specialist surgeons, to determine if the survival
advantage associated with specialist care is maintained with longer follow-up and persists after the introduction of screening. Using
the West of Scotland Cancer Registry, all 7197 women treated for breast cancer in a 15-year time period (1980–1994) in a
geographically defined cohort were followed up for an average of 9 years, and pathological stage and socioeconomic status were
linked with mortality data. We show that the caseload of specialists has increased substantially (from 11 to 59% of the total workload)
and that smaller cancers have been selectively referred. However, even after allowing for pathological stage, socioeconomic status
and method of detection, specialist treatment was associated with a significantly lower risk of dying (prescreening: relative risk of
dying¼0.83, 95% CI¼0.75–0.92; post-screening: relative risk of dying¼0.89, 95% CI¼0.78–1.00). We conclude that this survival
benefit is most consistent with effective surgical management rather than selective referral, the influx of screen-detected cancers or
adjuvant therapies.
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Many studies have shown that treatment of breast cancer differs
widely between types of hospital, geographical area and caseload of
treating surgeon (LeeFeldstein et al, 1994; Sainsbury et al, 1995a,
b). In an attempt to minimise variability, the Kings Fund (Kings’
Fund Forum Consensus Statement, 1986) and other professional
associations subsequently (National Institutes of Health Consensus
Conference, 1991) produced guidelines of treatment. All these
guidelines recommend a policy of referral to a designated breast
cancer team or specialist. However, in contrast to the number of
guidelines published recommending specialist treatment, only
three studies have reported a survival advantage associated with
specialist care (Sainsbury et al, 1995a; Gillis and Hole, 1996). These
were based on treatment that may be outdated, had limited follow-
up and were conducted in the prescreening era. It is unclear
whether the survival advantage demonstrated was a temporary
delay to disease progression or a ‘curative’ advantage that persists
with longer follow-up. In addition, none of these studies could
ascertain the nature of the survival advantage associated with
specialist treatment. Possible causes may include more unified
multidisciplinary treatment, greater use of adjuvant therapies,
selective referral and better case-mix. Indeed, the very implemen-
tation of protocols of treatment has been reported to reduce
variability in treatment and improve outcome (Winstanley et al,
1995).
Population-based screening was introduced in 1988. A series of
quality assurance guidelines were produced to ensure appropriate
treatment of small screen-detected cancers, and included recom-
mendations on pathological analysis, referral to specialist centres,
multidisciplinary meetings and protocols. Thus, both referral of
these small screen-detected cancers and treatment patterns may
have changed, in addition to any impact of screening on the
natural history of breast cancer itself.
The aim of this study is three-fold: firstly, to establish the impact
of screening on the caseload and case-mix of specialist surgeons.
Secondly, to determine if the survival advantage demonstrated in
the prescreening era is maintained with longer follow-up, and
thirdly, to ascertain if the survival advantage associated with
specialist treatment persists after the introduction of screening.
PATIENTS AND METHODS
All women aged under 75 years with a histologically proven
invasive breast cancer diagnosed between 1 January 1980
and 31 December 1994 were identified through the West of
Scotland Cancer Registry. The study population was defined
geographically using postcode sectors and formed the
catchment areas for 10 hospitals and two screening centres
(population base 1.5 million). Socioeconomic status was based
on postcode sectors using the Carstairs’ deprivation index
(Carstairs and Morris, 1988).
In total, 7673 women were identified and the pathology reports
of 7197 (94%) were reviewed. The following pathological details
were recorded: tumour size, axillary lymph node status (number
examined and number positive) and grade. Dates and causes of
death were obtained from the Registrar General for Scotland and Revised 17 February 2003; accepted 12 March 2003
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Screening Program started in June 1988 in the study area. Women
with screen-detected cancers were identified from linkage with the
breast screening centres that serve the population base.
Surgeons were selected as specialists for the present purpose, as
in the previous study based on local surgeons’ perception of who
had a special interest in breast cancer, (Gillis and Hole, 1996). Our
aim in this study was not to define a specialist, nor to determine
the nature of a previously demonstrated survival advantage, but to
ascertain if the concept of specialisation was applicable in the
postscreening era. Specialist surgeons had several characteristics
in common: the setting up of a dedicated breast clinic, a defined
association with pathologists and oncologists, entry into clinical
trials, and keeping a dedicated record of women with breast cancer
under their care. These characteristics were not used as selection
criteria, but clearly reflect a dedicated interest in breast cancer
treatment.
Cox’s proportional hazards model (Cox, 1972) was used to
analyse survival patterns, allowing a relative benefit to be
calculated after adjusting for differences in case-mix. Adjustment
was made for age group (o50, 50–64, 65–74 years), socio-
economic status (Carstairs categories: 1,2¼affluent; 3–
5¼intermediate; 6,7¼deprived), pathological tumour size (o10,
10–19, 20–39, 40þ mm), nodal status (positive, negative),
timeperiod (Period I¼1/1/80–31/12/83, Period II¼1/1/84–30/6/
88, Period III¼1/7/88–30/9/91, Period IV¼1/10/91–31/12/94)
and method of detection (symptomatic or screen-detected). The
prescreening era consisted of time periods I and II (1/1/80–30/6/
88), and the postscreening era of time periods III and IV (1/7/88–
21/12/94).
The caseload of specialist surgeons was examined firstly as a
percentage of the total workload each year. The caseload was then
examined for the pre and postscreening eras, firstly by the
contribution made by each age category to the total workload, and
secondly by the percentage of women in each age category treated
by specialists. The case-mix of the specialists and nonspecialists
was then compared in each screening era by tumour size, nodal
status and deprivation category. The 5- and 10-year survival rates
for women treated by specialists and nonspecialist surgeons were
estimated using the Kaplan–Meier technique. The hazard ratio for
women treated by specialists relative to nonspecialists was
compared for both the prescreening and post screening eras with
adjustment made for tumour size, nodal status, age, deprivation
category and method of detection.
RESULTS
The percentage of women treated by specialists increased steadily
from 11 to 59% of the total workload over the period of the study
(Figure 1). In the prescreening era, specialists treated more women
in the intermediate age category (47 vs 41%), and nonspecialists
saw more women in the older age category (24 vs 31%) (Table 1).
Postscreening, the difference in the age distribution was more
pronounced (women o50 years¼55% vs 44%, 65þyears¼21%
vs 30%). The percentage of all women in each age category treated
by specialists doubled (o50 years from 25 to 50%, 50–64 years
from 26 to 58%, 65þ years from 20 to 43%).
The case-mix and caseload were similarly analysed by tumour
size, nodal status and deprivation category (Table 2). Prior to
screening, the only significant difference in case-mix between
specialists and nonspecialists was the distribution by socio-
economic status (specialists treating more women in the affluent
and deprived categories), although the trend across the deprivation
categories was not significant. However, in the postscreening era,
specialists treated women with smaller cancers (o10mm: 16 vs
5%, 10–19mm: 36 vs 33%, 20–39mm: 37 vs 47%, 40þmm: 11 vs
15%; Po0.001). The distribution of nodal status was also
significantly different, although both groups treated a higher
percentage of node-negative women postscreening.
The 5-year survival of all women, irrespective of who treated
them, improved from 60% in the prescreening era to 73%
postscreening (relative hazard ratio (RHR))¼0.58, 95%
CI¼0.53–0.62, Po0.001 adjusted for age). This could not be
accounted for by changes in patterns of treatment, tumour size,
nodal status, deprivation category, screening status or age-
distribution (RHR¼0.77, 95% CI¼0.71–0.83, Po0.001, after
allowing for these variables).
The survival advantage associated with specialist treatment of
women in the prescreening era persists with the addition of 4 extra
years of follow-up, compared with our previous publication
(RHR¼0.83, Po0.001, Table 3). This benefit was also seen in
the postscreening era (RHR¼0.89, 95% CI¼0.78–1.00, adjusted
for tumour size, nodal status, deprivation category, screening
status and age). However, the survival benefit associated with
specialist treatment decreased in the postscreening era from a 17%
reduction in the risk of dying (RHR¼0.83 prescreening) to an
11% reduction (RHR¼0.89 postscreening). Analysing breast-
cancer-specific mortality did not alter this survival advantage.
The reduction in the risk of death associated with specialist
treatment was seen in those women with tumours smaller than
4cm (Table 4). The survival benefit was maximal in women with
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Figure 1 Percentage of all women treated by speciality of treating
surgeon by year of diagnosis.
Table 1 Caseload of specialist and non-specialist surgeons by time
period and age
Age
Specialists Nonspecialists
%t r e a t e db y
Time period (years) n % n % specialists
Prescreening
o50 269 29 796 28 25
50–64 427 47 1184 41 26
65+ 221 24 889 31 20
Total 917 100 2869 100 24
Postscreening
o50 430 24 421 26 50
50–64 980 55 717 44 58
65+ 369 21 494 30 43
Total 1779 100 1632 100 52
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ytumours smaller than 4cm (8% difference in 5-year survival), with
4þ nodes positive (17% difference in 5-year survival), in women
aged 50–64 years (13% difference in 5-year survival), and in the
most deprived women (10% difference in 5-year survival).
DISCUSSION
This study has shown that while the caseload of specialists has
steadily increased over a 15-year period and the case-mix has
altered with the implementation of the national screening
programme, the survival advantage associated with specialist
treatment has persisted with longer-term follow-up (median 13
years) and is also apparent in the postscreening cohort of women
(median follow-up 6 years).
In this and the previous study (Gillis and Hole, 1996), surgeons
were chosen as specialists on the basis of local surgeons’ opinions
of who exhibited a particular interest in breast cancer. The
specialists shared several common characteristics, for example,
keeping separate records of women they treated for breast cancer,
entry into clinical trials, and a multidisciplinary approach to
treatment. While these are vague characteristics, it must be
remembered that at the time of that study there was no
subspecialisation of surgical services. Indeed, the definition of
‘specialisation’ remains very variable. Other studies have used
hospital type (McArthy and Bore, 1991; Basnett et al,1 9 9 2 ) ,c a s e l o a d
(Sainsbury et al, 1995a), affiliation with oncological services
(Scorpiglione et al, 1995) and membership of local associations
(Sainsbury et al, 1995b). While these criteria may allow simple
differentiation into contrasting groups, they are also indirect
measures of adequate and appropriate treatment. Thus, we feel
that although our definition is subjective and not widely applicable,
it has validity, being based on the opinion of peers, and accurately
represents the focused training, dedicated interest, awareness of
Table 2 Case-mix of specialist and nonspecialist surgeons by time period and age
Specialists Nonspecialists
Time period Factor n % n % % treated by specialists
Prescreening
Tumour size (mm) o10 34 5 94 5 26
10–19 180 25 534 26 25
20–39 337 46 972 47 26
40+ 173 24 448 22 28
w
2¼0.75, P¼0.39
Nodal status Negative 387 50 837 46 32
Positive 388 50 983 54 28
w
2¼3.24, P¼0.07
Deprivation category Affluent 231 25 554 19 29
Intermediate 345 38 1366 48 20
Deprived 341 37 949 33 25
w
2¼0.41, P¼0.52
Postscreening
Tumour size (mm) o10 250 16 63 5 80
10–19 549 36 441 33 55
20–39 559 37 638 47 47
40+ 168 11 199 15 46
w
2¼90.90, Po0.001
Nodal status Negative 848 59 639 55 57
Positive 586 41 525 45 53
w
2¼4.54, P¼0.03
Deprivation category Affluent 446 25 294 18 60
Intermediate 767 43 840 52 48
Deprived 566 32 498 30 53
w
2¼5.42, P¼0.02
Table 3 Survival of women treated by specialist and nonspecialist surgeons by time period
Specialists Nonspecialists
Time period 5years 10years RHR 5years 10years RHR
All cause mortality
Prescreening 67% 49% 0.83 58% 42% 1
(0.75–0.92) (Baseline)
Postscreening 77% 0.89 70% 1
(0.78–1.00) (Baseline)
Breastcancer specific mortality
Prescreening
71% 64% 0.82 64% 52% 1
(0.73–0.92) (Baseline)
Postscreening 81% 0.89 75% 1
(0.77–1.02) (Baseline)
RHR¼Relative hazard ratio (95% confidence limits), adjusted for tumour size, age group, socioeconomic status, year of diagnosis
and method of detection.
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underlies the premise of better treatment with specialisation.
The caseload of specialists doubled in the time period studied.
Unexpectedly, this increased workload was not due solely to an
influx of screen-detected cancers, but a steady incremental growth
that started before screening. Although the pre-screening case-mix
between specialists and nonspecialists was the same, after screening
there was selective referral to specialists of younger women and
smaller, screen-detected tumours. Almost half of all women treated
by specialists in the age group 50–64 years, the age group offered
screening, were screen-detected. However, it is interesting that in
this same age group, 14% of women treated by nonspecialists had
also been screen-detected. This re-enforces our premise that
specialisation is not easily categorised, and that simply defining
categories, for example, teaching hospitals vs district hospitals, does
not necessarily correlate with quality of treatment.
Survival differences between the two groups of surgeons could
be accounted for by differences in tumour size (lead-time bias) and
also by method of tumour detection (length-time bias). Length-
time bias was a possible confounding factor as screening may
preferentially detect slower growing, more favourable tumours
(Duffy et al, 1991; Klemi et al, 1992). This was confirmed, as the
method of detection remained a highly significant variable in the
survival analysis after allowing for all other factors (RHR¼0.59,
Po0.001).
We examined survival by two well-recognised methods to allow
for the difference demonstrated in case-mix between specialists
and nonspecialists. Firstly a multivariate analysis was performed
and variables of tumour size, nodal status, age, method of
detection and deprivation category were included as independent
variables. Secondly, the data were stratified according to the above
variables with the others included as independent variables. The
benefit associated with specialist treatment was maximal in
smaller, node-positive tumours, but also seen in all ages and
socioeconomic groups. Given the size of the survival differences
and the groups in which it is maximally seen, the survival benefit
would not therefore be consistent with purely differential
prescription of chemotherapy or endocrine therapy.
It is interesting to note that the survival benefit was not seen in
tumours larger than 4cm. Recent evidence suggests that local
treatment and thus local recurrence may lead to dissemination of
disease and poorer survival (Overgaard et al, 1997; Ragaz et al,
1997). It is very unlikely that tumours greater than 4cm would have
been suitable for or treated by breast conserving surgery. Thus, it is
unsurprising that there is no difference in survival between
specialists and nonspecialists in women with large tumours, as
both will have been equally treated with mastectomy. Furthermore,
women with advanced tumours are more likely to have dissemi-
nated disease at the time of diagnosis, and thus it is logical that any
survival difference caused by local treatment will be overwhelmed
by the overall poorer survival in this group of women.
Overall, 5-year survival between the two time periods has
improved considerably (from 60 to 73%). The cause of this
improvement is hard to determine, but could not be accounted for
by changes in referral patterns, screening or case-mix in the
multivariate analysis. It is unlikely that this can be solely because
of increasing use of chemotherapy or endocrine therapy given the
magnitude of this improvement.
We conclude that while the nature of this survival benefit remains
elusive, we are confident that it is real, persistent, and most
consistent with effective surgical management rather than selective
referral, the influx of screen-detected cancers, or adjuvant therapies.
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